Summary
Serological exposure markers are a promising tool for surveillance and targeted interventions for Plasmodium vivax malaria. P. vivax is closely related to the zoonotic parasite P. knowlesi, which also infects humans. P. vivax and P. knowlesi are co-endemic across much of South East Asia, making it important to design P. vivax serological markers that minimise cross-reactivity in this region. Our objective was to determine the degree of IgG antibody cross-reactivity against a panel of P. vivax serological markers in samples from human participants with P. knowlesi malaria. We observed higher levels of IgG antibody reactivity against P. vivax proteins that had high levels of sequence identity with their P. knowlesi ortholog. IgG reactivity peaked at 7 days post P. knowlesi infection and was short-lived, with minimal responses detected at 1-year post-infection. Using these data, we designed a panel of 8 P. vivax proteins with low-levels of cross-reactivity with P. knowlesi. This panel was able to accurately classify recent P. vivax infections whilst reducing misclassification of recent P. knowlesi infections.
Competing Interest Statement
RL, MW, TT and IM are inventors on filed patent PCT/US17/67926 on a system, method, apparatus and diagnostic test for P. vivax. MH was an employee of the company CellFree Sciences Co., Ltd. All other authors declare they have no competing interests.
Funding Statement
This study was funded by: WEHI Innovation Fund (RL, TT, IM) Clinical Trials Funding: Malaysian Ministry of Health (grant number BP00500420), the Asia Pacific Malaria Elimination Network (108-07), and the Australian National Health and Medical Research Council (NHMRC; 1037304, 1045156, 115680) NHMRC Fellowships to NMA #1135820, MJG #1138860 and RL #1173210 NHMRC grants #1092789, #1134989, #1132975 and #1043345 (IM)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Samples from two clinical trials conducted in Sabah, Malaysia, were used for this study (ACTKNOW and PACKNOW). Ethical approvals for these studies were obtained from the Human Research Ethics Committee at the Menzies School of Health Research, Darwin, Australia (approval numbers 2012-1815 and 16-2544) and the Medical Research and Ethics Committee of the Ministry of Health Malaysia, Malaysia (approval numbers NMRR-12-89-11005 and NMRR-16-29088). All patients gave written informed consent or an attending relative gave informed consent. Ethical approval was provided by the Human Research Ethics Committee at the Walter and Eliza Hall Institute of Medical Research for use of the Malaysian and negative control samples in Melbourne (approval number 14/02).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are contained in the manuscript (with additional files containing the antibody and patient data).